Biotech Companies With Advantageous Tech for Cancer Patients

Wednesday, November 1, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+ News Commentary

LAS VEGAS, November 1, 2017 /PRNewswire/ --

There has been

progression in both, earlier detection of cancer and cancer therapies. Despite this headway, cancer remains a worldwide healthcare problem. Cancer is the second leading cause of death globally and approximately 8.8 million people died from cancer in
2015. Approximately 1 in 6 deaths is due to cancer. So are biotechnology companies actually making headway in this gloomy area of human health?

The answer is yes. The major goal of their research is to identify genetic expression of cancer cells and use this knowledge to develop effective diagnostic, treatment, and prevention regimens. Estimated global spending for oncology medicines is expected to grow from $107 billion in 2015 to $150 billion by 2020 as lifespans lengthen across the developed world.

It's important to keep up on biotechnology companies who are committed and focused on cancer research. A few companies to keep track of include: Propanc Biopharma, Inc. (OTC: PPCB), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), ImmunoGen, Inc. (NASDAQ: IMGN), Verastem, Inc. (NASDAQ: VSTM).

Propanc Biopharma, Inc. (OTCQB: PPCB)

Market Cap: $1.2M, current share price: $.15 

PPCB is leading the way in cancer research as a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancer. At the end of last month the Company had a major announcement regarding their lead drug, PRP, and its therapeutic potential to improve outcomes for cancer patients. Their most recent scientific study observed an extraordinary reduction of Epithelial to Mesenchymal Transition (EMT) markers from the use of PRP. What they found is that PRP reverses the EMT process which totally stops tumor progression and metastasis. Not only is the EMT process reversed, but PRP blocks the development of Cancer Stem Cells (CSCs). Keep yourself updated on PPCB as the Company moves closer and closer to cancer therapies.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO)

Market Cap: $563.02M, current share price: $6.24 

INO, a Company striving to take immunotherapy to the next level in the fight against cancer and infectious diseases, announced today that it has initiated a Phase II study to evaluate the combination of two immunotherapy candidates and Roche Holding AG's RHHBY anti-PDL1 inhibitor, Tecentriq, in advanced bladder cancer. It is estimated that almost 430,000 are diagnosed with bladder cancer with 165,000 deaths worldwide every year.

ImmunoGen, Inc. (NASDAQ: IMGN)

Market Cap: $714.939M, current share price: $6.19 

IMGN, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer. Just today they received huge news that the U.S. Food and Drug Administration (FDA) has completed the safety review of its investigational new drug (IND) application for IMGN632 in patients with CD123-positive hematological malignancies including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Verastem, Inc. (NASDAQ: VSTM)

Market Cap: $163.34M, current share price: $4.15 

VSTM is a clinical stage biopharmaceutical company also focuses on discovering and developing drugs to improve outcomes for patients with cancer. Today the Company announced today announced payment of a $6 million milestone to Infinity Pharmaceuticals, Inc., representing the first milestone under the duvelisib license agreement between Verastem and Infinity. Last month VSTM reported that the Phase 3 DUO study met its primary endpoint with oral duvelisib monotherapy demonstrating superiority over ofatumumab for progression free survival (PFS) in patients with CLL/SLL.

Content Provided By: Microcap Speculators

Email: Phone: +1-702-720-6310 Website:

For Full Microcap Speculators Legal Disclaimer Click Here .

DISCLAIMER: (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact: FN Media Group, LLC - +1-(954)345-0611



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store